Key studies and research groups

• The Cervical Cancer group - Cervical Cancer Prevention & Management: This group led by Prof Mara Kyrgiou is integrating genetic, epigenetic, microbiome and metabonomic platforms to explore what promotes cervical carcinogenesis and improve prevention, early detection and improved treatment. Genome and epigenome association studies, clinical trials and epidemiological research is a focus.
• Cancer & Metabolism Group – Obesity & Diabetes: This group led by Prof Mara Kyrgiou is exploring the impact of obesity and metabolic disorders in the development, management and prognosis of gynaecological malignancies. The role of genital tract microbiome and the use of organoids in endometrial cancer is a focus.
• Ovarian cancer group: This group is led by Prof Ghaem-Maghami exploring immunomics and development of immunological therapies in ovarian cancer, the use of novel technologies in intraoperative diagnosis and treatment of gynaecological cancers and the use of biomarkers to predict surgical outcome.
• Cell Signalling Group: This group is led by Dr Nick Dibb and focuses on receptor signalling and kinase inhibitor studies in cancer & reproduction and RNA splicing and microRNA function in stem cells.
• Fertility and Pregnancy Care After Cancer Treatment
• Women's Cancers
• The NOVEL trial: funded by the National Institute of Health Research is looking into the value of HPV vaccine after treatment for cervical precancer.

Professor Maria Kyrgiou

Head of Gynaecological Oncology

Professor Maria Kyrgiou is Chair in Gynaecological Oncology at Imperial College London and a Consultant Surgeon in Gynaecology and Gynaecologic Oncology at the West London Gynaecological Cancer Centre, Imperial Healthcare NHS Trust. Her main clinical interest is in gynaecologic and gynaecologic cancer surgery and minimal access surgery.

Further information on Prof Mara Kyrgiou